FLT3 and acute myeloid leukemia: Recently, several tyrosine kinase inhibitors (TKIs, e.g., sorafenib, midostaurin, quizartinib, and crenolanib) have been introduced for the treatment of patients with r/r AML with FLT3 mutations (predominantly ITD).